Keya Medical announced on April 13 that its DeepVessel 3D Visualization Processing Software has received regulatory approval in China.
This is the second approval Keya Medical has received in China for a deep learning-based software medical device over the past year. In 2020, Keya Medical became the first company in China to receive approval from the National Medical Products Administration (NMPA) for a deep learning-based software medical device. The NMPA-approved software, DeepVessel FFR, uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CTA) scans.
The approval of the DeepVessel 3D Visualization Processing Software in China further demonstrates Keya Medical’s mission to develop a comprehensive R&D product pipeline that will deliver clinical value at all stages in the patient care process. Keya Medical will continue to develop its diagnostic and treatment product lines for use in early screening, diagnosis, treatment, and post-treatment maintenance.
About Keya Medical
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating products that deliver clinical value at all stages in the patient care process from early screening, diagnosis, and treatment to post-treatment maintenance. Since 2016, Keya Medical has collaborated with more than 725 hospitals worldwide to improve care delivery by optimizing efficiency, improving accuracy, and increasing precision. To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.